Impact of Cannabis Use on the Development of Psychotic Disorders

Current Addiction Reports

Volumn 1, Issue 2, 2014, Pages 115-128

  Wilkinson, Samuel T ^a   Radhakrishnan, Rajiv ^a   D’Souza, Deepak Cyril ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Cannabis; Psychosis; Psychotic disorders; Schizophrenia

Indexed keywords

EID: 84938748507     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-014-0018-7     Document Type: Review

References (171)

1. Devane WA, Dysarz 3rd FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605–13.
2. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142(2):278–87.
3. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66.
4. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78(1):43–50.
5. Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C, et al. Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology. 2010;151(12):5818–29.
6. Bacci A, Huguenard JR, Prince DA. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature. 2004;431(7006):312–6.
7. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. 2005;25(29):6845–56.
8. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. 2010;169(4):1651–61.
9. Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P, et al. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol. 2007;97(4):2580–9.
10. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex. 2007;17(1):175–91. Study detailing the distribution of cannabinoid receptors in the brain.
11. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience. 2000;100(4):797–804.
12. Ali AB, Todorova M. Asynchronous release of GABA via tonic cannabinoid receptor activation at identified interneuron synapses in rat CA1. Eur J Neurosci. 2010;31(7):1196–207.
13. Foldy C, Neu A, Jones MV, Soltesz I. Presynaptic, activity-dependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci. 2006;26(5):1465–9.
14. Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol. 2005;146(7):913–5.
15. Elsohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–48.
16. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.
17. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260(1):201–9.
18. Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24(1):51–64.
19. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306–7.
20. Mechoulam, Hanus. In: Castle D, Murray R, editors. Marijuana and Madness. Cambridge: Cambridge University Press; 1994. p. 1–18:.
21. Solomons K, Neppe VM, Kuyl JM. Toxic cannabis psychosis is a valid entity. S Afr Med J. 1990;78(8):476–81.
22. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195(6):488–91.
23. Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R. Cannabis-associated psychosis with hypomanic features. Lancet. 1982;2(8312):1364–6.
24. Solomons K, Neppe VM. Cannabis–its clinical effects. S Afr Med J. 1989;76(3):102–4.
25. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–72. A randomized, double-blind, placebo-controlled, crossover study showing that THC can induce a range of positive, negative, and cognitive symptoms in healthy individuals that bear some resemblance to the symptoms of schizophrenia.
26. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19–27.
27. Sherrica T, Fantegrossi WE. Synthetic Cannabinoids: Pharmacology, Behavioral Effects and Abuse Potential. Curr Addict Rep. In Press
28. Warnock J. Insanity from hasheesh. J Mental Sci. 1903;49:96–110.
29. Radhakrishnan R AP, Sewell RA, Skosnik PD, Ranganathan M, D’Souza DC. Cannabis, Cannabinoids and the link with psychosis. In: Madras B, Kuhar MJ, editors. The Effects of Drug Abuse on the Human Nervous System. San Diego,CA: Academic Press (Elsevier); 2014. p. 423–74. Comprehensive review of the association between cannabis use and psychosis.
30. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003;22(4):453–60.
31. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93(6):837–46.
32. Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs. Epub 2013 Dec 10.
33. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525–40.
34. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39(10):1607–16.
35. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav. 2000;66(1):175–81.
36. Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology. 1999;142(3):230–5.
37. Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, et al. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology (Berl). 2013;226(2):401–13.
38. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594–608. The only randomized, double-blind, placebo-controlled, crossover study showing that THC exacerbates symptoms in chronic, stable, medicated schizophrenia patients and that schizophrenia patients are more vulnerable to the effects of THC.
39. Ilan AB, Gevins A, Coleman M, Elsohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol. 2005;16(5–6):487–96.
40. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM. Effects of acute oral Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol. 2008;18(8):569–77.
41. D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, et al. Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Delta(9)-THC in Humans. Neuropsychopharmacology. 2012;37(7):1632–46.
42. van der Meer L, de Vos AE, Stiekema AP, Pijnenborg GH, van Tol MJ, Nolen WA, et al. Insight in schizophrenia: involvement of self-reflection networks? Schizophr Bull. 2013;39(6):1288–95.
43. Spronk D, Dumont GJ, Verkes RJ, de Bruijn ER. Acute effects of delta-9-tetrahydrocannabinol on performance monitoring in healthy volunteers. Front Behav Neurosci. 2011;5:59.
44. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11(2):100–13.
45. Singer W. Neuronal synchrony: a versatile code for the definition of relations? Neuron. 1999;24(1):49–65. 111–25.
46. Whittington MA, Faulkner HJ, Doheny HC, Traub RD. Neuronal fast oscillations as a target site for psychoactive drugs. Pharmacol Ther. 2000;86(2):171–90.
47. Melloni L, Molina C, Pena M, Torres D, Singer W, Rodriguez E. Synchronization of neural activity across cortical areas correlates with conscious perception. J Neurosci. 2007;27(11):2858–65.
48. Uhlhaas PJ, Pipa G, Lima B, Melloni L, Neuenschwander S, Nikolic D, et al. Neural synchrony in cortical networks: history, concept and current status. Front Integr Neurosci. 2009;3:17.
49. Wang XJ. Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev. 2010;90(3):1195–268.
50. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. 1999;19(11):4544–58.
51. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci. 2000;12(9):3239–49.
52. Morgan NH, Stanford IM, Woodhall GL. Modulation of network oscillatory activity and GABAergic synaptic transmission by CB1 cannabinoid receptors in the rat medial entorhinal cortex. Neural Plasticity. 2008;2008:808564.
53. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci. 2006;9(12):1526–33.
54. Reich CG, Karson MA, Karnup SV, Jones LM, Alger BE. Regulation of IPSP theta rhythm by muscarinic receptors and endocannabinoids in hippocampus. J Neurophysiol. 2005;94(6):4290–9.
55. Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry. 2008;63(11):1075–83.
56. Sales-Carbonell C, Rueda-Orozco PE, Soria-Gomez E, Buzsaki G, Marsicano G, Robbe D. Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony. Proc Natl Acad Sci USA. 2013;110(2):719–24.
57. Bocker KB, Hunault CC, Gerritsen J, Kruidenier M, Mensinga TT, Kenemans JL. Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans. J Cogn Neurosci. 2010;22(9):1906–16.
58. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–74.
59. Bossong MG, Jansma JM, Bhattacharyya S, Ramsey NF. Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or 9-tetrahydrocannabinol (THC). Prog Neuropsychopharmacol Biol Psychiatry. Epub 2013 Dec 29.
60. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, et al. Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012;69(1):27–36. Controlled laboratory imaging study showing the brain activation patterns associated with the psychotomimetic effects of THC.
61. Atakan Z, Bhattacharyya S, Allen P, Martin-Santos R, Crippa JA, Borgwardt SJ, et al. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Delta9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med. 2013;43(6):1255.
62. Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18 F-fallypride positron emission tomography study. PloS One. 2013;8(7):e70378.
63. Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014;14c:97–102.
64. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology. 2009;34(3):759–66.
65. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol. 2011;25(11):1462–8.
66. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage. 2009;48(1):186–90.
67. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008;198(4):587–603.
68. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010;24(11):1697–708.
69. Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, et al. Does olanzapine inhibit the psychomimetic effects of Delta(9)-tetrahydrocannabinol? J Psychopharmacol. 2012;26(10):1307–16.
70. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510–5. A retrospective review and follow-up of patients initially diagnosed with cannabis-induced psychosis who converted to schizophrenia.
71. Bernhardson G, Gunne LM. Forty-six cases of psychosis in cannabis abusers. Int J Addict. 1972;7(1):9–16.
72. Harding T, Knight F. Marihuana-modified mania. Arch Gen Psychiatry. 1973;29(5):635–7.
73. Mathers DC, Ghodse AH, Caan AW, Scott SA. Cannabis use in a large sample of acute psychiatric admissions. Br J Addict. 1991;86(6):779–84.
74. Carney MW, Bacelle L, Robinson B. Psychosis after cannabis abuse. Br Med J (Clin Res Ed). 1984;288(6423):1047.
75. Talbott JA, Teague JW. Marihuana psychosis: Acute toxic psychosis associated with the use of cannabis derivatives. JAMA. 1969;210:299–302.
76. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry. 1972;27:133–6.
77. Wylie AS, Scott RT, Burnett SJ. Psychosis due to "skunk". BMJ. 1995;311(6997):125.
78. Basu D, Malhotra A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. A case–control study from India. Eur Addict Res. 1999;5(2):71–3.
79. Chaudry HR, Moss HB, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict. 1991;86(9):1075–81.
80. Cohen SI. Cannabis consumption and schizophrenia. Br J Psychiatry. 1994;165(3):410–1.
81. Thacore VR. Bhang psychosis. Br J Psychiatry. 1973;123(573):225–9.
82. Thacore VR, Shukla SR. Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry. 1976;33(3):383–6.
83. Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives JAMA. 1969;210(2):299–302.
84. Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. JAMA. 1971;216(3):486–92.
85. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352(9140):1611–6.
86. Aggarwal M, Banerjee A, Singh SM, Mattoo SK, Basu D. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications. Asian J Psychiatr. 2012;5(3):220–4.
87. Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94–9.
88. Pihlajamaa J, Suvisaari J, Henriksson M, Heila H, Karjalainen E, Koskela J, et al. The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. Nord J Psychiatry. 2008;62(3):198–203.
89. Rounsaville BJ. DSM-V research agenda: substance abuse/psychosis comorbidity. Schizophr Bull. 2007;33(4):947–52.
90. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol. 2007;78:289–326. Review of epidemiological and neurobiological evidence for the association of cannabis and psychosis, including a possible causal role.
91. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483–6. One of the first epidemiological studies (N > 50,000) showing an association between cannabis exposure and risk of psychosis.
92. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199. A follow-up of the Swedish military cohort (N > 50,000), in response to hypotheses that the cannabis–psychosis association could be explained by other drugs or personality traits.
93. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med. 2012;42(6):1321–8. Additional follow-up at 35 years of the Swedish military cohort, confirming an increased risk of psychosis for early and heavy cannabis users.
94. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3. One of the first prospective cohort studies showing an association between early cannabis exposure and risk for psychosis.
95. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–27.
96. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (Clin Res Ed). 2011;342:d738.
97. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction (Abingdon, England). 2005;100(3):354–66.
98. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence.[see comment]. Br J Psychiatry. 2004;184:110–7.
99. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28. A systematic review of the association between cannabis and psychosis and cannabis and affective disorders.
100. Henquet C, Murray R, Linszen D, van Os J. The Environment and Schizophrenia: The Role of Cannabis Use. Schizophr Bull. 2005;31(3):608–12.
101. Gage SH, Zammit S, Hickman M. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep. 2013;5(2). Brief review suggesting that, while important neurobiologically, there is still much unkown with regards to the cannabis–schizophrenia connection.
102. Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125(1):45–53.
103. Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, et al. Cannabis use disorder and age at onset of psychosis–a study in first-episode patients. Schizophr Res. 2011;129(1):52–6.
104. Cunha PJ, Rosa PG, Ayres Ade M, Duran FL, Santos LC, Scazufca M, et al. Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res. 2013;147(2–3):209–15.
105. Allebeck P, Adamsson C, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County [erratum appears in Acta Psychiatr Scand 1993 Oct;88(4):304]. Acta Psychiatr Scand. 1993;88(1):21–4.
106. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273–9.
107. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry. 1996;40(11):1155–63.
108. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34(3):468–75.
109. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen psychiatry. 2011;68(6):555–61. Systematic meta-analysis evaluating 83 studies that investigate the association with cannabis use on the age of onset of psychosis.
110. Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull. 2011;37(3):631–9.
111. Griffith-Lendering MF, Wigman JT. Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, et al. Cannabis use and vulnerability for psychosis in early adolescence–a TRAILS study. Addiction. 2013;108(4):733–40.
112. Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1–3):197–202.
113. Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav. 2007;86(2):189–99.
114. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist. 2007;13(2):109–14. Concise review on the neurobiological role of the endocannabinoid system.
115. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105(25):8760–5.
116. Watson S, Chambers D, Hobbs C, Doherty P, Graham A. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol Cell Neurosci. 2008;38(1):89–97.
117. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A. 2005;102(52):19115–20.
118. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212–6.
119. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci. 2006;26(5):1551–61.
120. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci. 2007;28(2):83–92. A review of the role that the endocannabinoid system plays in brain development.
121. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000;23(1):14–20.
122. Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol. 2004;66(2):204–8.
123. Ruiz-Veguilla M, Barrigon ML, Hernandez L, Rubio JL, Gurpegui M, Sarramea F, et al. Dose–response effect between cannabis use and psychosis liability in a non-clinical population: evidence from a snowball sample. J Psychiatr Res. 2013;47(8):1036–43.
124. O'Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol. 2004;18(4):502–8.
125. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, et al. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology. 2008;33(5):1113–26.
126. Cha YM, White AM, Kuhn CM, Wilson WA, Swartzwelder HS. Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav. 2006;83(3):448–55.
127. Schneider M, Schomig E, Leweke FM. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol. 2008;13(3–4):345–57.
128. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13(2):253–63.
129. Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr Bull. 2013;39(2):251–4.
130. Myles N, Newall H, Compton MT, Curtis J, Nielssen O, Large M. The age at onset of psychosis and tobacco use: a systematic meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2012;47(8):1243–50.
131. Pope Jr HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep. 2001;3(6):507–12.
132. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology. 2006;185(3):358–68.
133. Pope Jr HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909–15. One of the first studies showing the resolution of cognitive deficits with abstinence from cannnabis.
134. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana–a comparison with pre-drug performance. Neurotoxicol Teratol. 2005;27(2):231–9.
135. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci. 1995;56(23–24):2119–26.
136. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1–8.
137. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, et al. Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med. 2004;34(7):1239–50.
138. Pope Jr HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 2003;69(3):303–10.
139. Pope Jr HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol. 2002;42(11 Suppl):41S–7S.
140. Pope Jr HG. Cannabis, cognition, and residual confounding. JAMA. 2002;287(9):1172–4.
141. Verdejo-Garcia AJ, Lopez-Torrecillas F. Aguilar de Arcos F, Perez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav. 2005;30(1):89–101.
142. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337–43.
143. Verdejo-Garcia A, Bechara A, Recknor EC, Perez-Garcia M. Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction. J Int Neuropsychol Soc. 2006;12(3):405–15.
144. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Nat Acad Sci U S A. 2012;109(40):E2657–64. A longitudinal, prospective population-based sample investigating the association of cannabis use and IQ.
145. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–7.
146. Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North Am. 1986;9(3):533–45.
147. Halikas J, Weller R, Morse C. Effects of regular marijuana use on sexual performance. J Psychoactive Drugs. 1982;14(1–2):59–70.
148. Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. J Psychiatr Nurs Ment Health Serv. 1971;9(6):9–16.
149. Rovai L, Maremmani AG, Pacini M, Pani PP, Rugani F, Lamanna F, et al. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv Psichiatr. 2013;48(1):1–9.
150. Hollister LE. Cannabis–1988. Acta Psychiatr Scand Suppl. 1988;345:108–18.
151. Bersani G, Orlandi V, Kotzalidis G, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci. 2002;252(2):86–92.
152. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res. 2004;71(1):61–4.
153. 158 Met and Beyond. Biologic Psychiatry. 2006;60(2):141–51.
154. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biologic Psychiatry. 2005;57(10):1117–27. The first study investigating the gene COMT as a possible moderator of the cannabis–psychosis association; a prospective population-based cohort.
155. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 2007;191:402–7.
156. Kantrowitz JT, Nolan KA, Sen S, Simen AA, Lachman HM, Bowers Jr MB. Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. Psychiatr Q. 2009;80(4):213–8.
157. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68(2):148–57. The first study suggesting a role for AKT1 in moderating the risk of psychosis associated with cannabis use.
158. Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry. 2011;199(5):380–5.
159. Estrada G, Fatjo-Vilas M, Munoz MJ, Pulido G, Minano MJ, Toledo E, et al. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand. 2011;123(6):485–92.
160. Costas J, Sanjuan J, Ramos-Rios R, Paz E, Agra S, Tolosa A, et al. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr Res. 2011;127(1–3):22–7.
161. 2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cellular signalling. 2003;15(9):851–9.
162. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological psychiatry. 2012;72(10):811–6. A case–control study confirming a possible role for the gene AKT1 as a moderator of the cannabis–psychosis interaction.
163. van Winkel R, van Beveren NJ, Simons C. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology. 2011;36(12):2529–37. A case–control study suggesting a role for AKT1 polymorphisms in conferring vulnerability to cannabis-associated risk of psychotic disorder.
164. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry. 2012;17(12):1152–5.
165. Decoster J, van Os J, Kenis G, Henquet C, Peuskens J, De Hert M, et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):363–9.
166. Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull. 2008;34(3):580–5.
167. Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med. 2010;40(10):1627–34.
168. Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, et al. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med. 2012;42(1):149–59.
169. Kuepper R, Henquet C, Lieb R, Wittchen HU, van Os J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr Res. 2011;131(1–3):262–3.
170. 158Met polymorphism. Schizophr Res. 2013;150(1):303–11.
171. Alemany S, Arias B, Fatjo-Vilas M, Villa H, Moya J, Ibanez MI, et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand. 2014;129(1):54–62.